Form 4: Arcutis Biotherapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Christopher Peetz, a Director of Arcutis Biotherapeutics, Inc., reported multiple transactions in common stock on July 15, 2026.
Summary
- Grant/award: acquired 4,315 Common Stock on July 15, 2026; holds 4,315 after (Direct).
- Grant/award: acquired 21,486 Stock Option (right to buy) on July 15, 2026; holds 21,486 after (Direct).
- Grant/award: acquired 13,010 Stock Option (right to buy) on July 15, 2026; holds 13,010 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Christopher Peetz — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-15 | Grant/award | Common Stock | 4,315 | — | — | 4,315 |
| 2026-07-15 | Grant/award | Stock Option (right to buy) | 21,486 | — | — | 21,486 |
| 2026-07-15 | Grant/award | Stock Option (right to buy) | 13,010 | — | — | 13,010 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-15 | Grant/award (4,315 shares) |
| 2026-07-15 | Grant/award (21,486 shares) |
| 2026-07-15 | Grant/award (13,010 shares) |
Keywords
insider transaction, Form 4, ARQT, Arcutis Biotherapeutics, Inc., neutral, Christopher Peetz
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.